Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors.
Bayliss, T., Robinson, D.A., Smith, V.C., Brand, S., McElroy, S.P., Torrie, L.S., Mpamhanga, C., Norval, S., Stojanovski, L., Brenk, R., Frearson, J.A., Read, K.D., Gilbert, I.H., Wyatt, P.G.(2017) J Med Chem 60: 9790-9806
- PubMed: 29125744 
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01255
- Primary Citation of Related Structures:  
5T5U, 5T6C, 5T6E, 5T6H - PubMed Abstract: 
N-Myristoyltransferase (NMT) represents a promising drug target within the parasitic protozoa Trypanosoma brucei (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness. We have previously validated T. brucei NMT as a promising druggable target for the treatment of HAT in both stages 1 and 2 of the disease. We report on the use of the previously reported DDD85646 (1) as a starting point for the design of a class of potent, brain penetrant inhibitors of T. brucei NMT.
Organizational Affiliation: 
Drug Discovery Unit, College of Life Sciences, University of Dundee , Sir James Black Centre, Dundee DD1 5EH, U.K.